GLP-1 trends 2025: real-world data, patient outcomes & future therapies
Few areas of medicine have captured public interest over the past two years quite like...
Topic
Marketplace (2)
Disparities in OUD treatment: Buprenorphine vs. naltrexone
Understanding disparities in opioid use disorder (OUD) treatment Pharmaceutical companies committed...
Gilead uses HealthVerity data to find liver-protective treatment
Antiretroviral therapy (ART) has transformed outcomes for people living with HIV, especially those...
Who's missing out? The truth behind food allergy treatment approvals
Mapping food allergy care with omalizumab and real-world data IgE-mediated food allergies (FAs)...
J&J's real-world bladder cancer study started in HealthVerity Marketplace
High-risk NMIBC: Disease overview and treatment approach Johnson & Johnson quickly identified and...
The Marketplace model is winning: key insights from our webinar
The HealthVerity Marketplace webinar wrapped up with a clear message. The Marketplace model is not...
The GLP-1 trend: What the real-world data reveals
GLP-1 Trends: Ozempic and Semaglutide drive a 587% spike in prescriptions Prescriptions for GLP-1...
Link between prostate cancer, mental health: The importance of real-world insights
Prostate cancer is the most common cancer among men, aside from skin cancer, and is known for being...
HealthVerity data strengthens regulatory submissions and clinical trials
Why data provenance matters for regulatory submissions and clinical trials Regulators increasingly...
Open claims vs. closed payer claims: What’s the difference?
Open claims and closed payer claims data are essential for understanding the status and activities...